The SDCCAG8 antibody targets the SDCCAG8 protein, encoded by the SDCCAG8 gene (Serologically Defined Colon Cancer Antigen 8), also known as CCCAP or HSPC142. This protein contains leucine zipper and coiled-coil domains, suggesting roles in protein-protein interactions and intracellular signaling. SDCCAG8 is implicated in ciliopathies, a group of disorders linked to defective cilia. Mutations in the SDCCAG8 gene are associated with Bardet-Biedl syndrome (BBS) and Senior-Løken syndrome, characterized by retinal degeneration, renal abnormalities, and developmental defects. The protein localizes to centrioles and basal bodies, critical for cilia formation and function, making it essential for studying ciliary biology and related diseases.
In cancer research, SDCCAG8 is explored as a potential biomarker due to its altered expression in colorectal and other cancers. Studies suggest its involvement in cell cycle regulation, DNA damage response, and interaction with BRCA1-BARD1 complexes, impacting genomic stability. SDCCAG8 antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate its expression patterns, subcellular localization, and functional roles in both physiological and pathological contexts. These tools are vital for elucidating SDCCAG8's contribution to ciliopathies, tumorigenesis, and cellular homeostasis, offering insights into therapeutic targeting and diagnostic applications.